Johnson & Johnson (NYSE:JNJ) Shares Unloaded Rep. Josh Gottheimer

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on April 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on March 7th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 3/24/2025.
• Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 3/24/2025.
• Sold $1,001 – $15,000 in shares of Flywire (NASDAQ:FLYW) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Disco (OTCMKTS:DSCSY) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Diageo (NYSE:DEO) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Shopify (NYSE:SHOP) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk (NYSE:TLK) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 3/19/2025.

Johnson & Johnson Trading Up 2.0 %

JNJ opened at $151.62 on Monday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The business’s 50 day moving average is $159.40 and its two-hundred day moving average is $155.17. The firm has a market cap of $365.39 billion, a price-to-earnings ratio of 22.80, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the firm earned $2.29 EPS. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Hedge Funds Weigh In On Johnson & Johnson

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. IFS Advisors LLC grew its holdings in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares during the last quarter. WealthTrak Capital Management LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at $29,000. Bay Harbor Wealth Management LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth about $32,000. Finally, Conquis Financial LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at about $33,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent research reports. Bank of America decreased their price objective on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $163.00 to $164.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 9th. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Finally, Raymond James reduced their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Eight research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $171.67.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.